Vanda Pharmaceuticals CEO Mihael Polymeropoulos' 2019 pay stays at $4.3M
Vanda Pharmaceuticals reports 2019 executive compensation
By ExecPay News
Published: April 22, 2020
Vanda Pharmaceuticals reported fiscal year 2019 executive compensation information on April 22, 2020.
In 2019, five executives at Vanda Pharmaceuticals received on average a compensation package of $2.6M, a 10% decrease compared to previous year.
Average pay of disclosed executives at Vanda Pharmaceuticals
Mihael H. Polymeropoulos, Chief Executive Officer, received $4.3M in total, which is about the same as previous year. 38% of Polymeropoulos' compensation, or $1.6M, was in option awards. Polymeropoulos also received $675K in non-equity incentive plan, $721K in salary, $1.2M in stock awards, as well as $35K in other compensation.
Gian Piero Reverberi, Former Senior Vice President, Chief Commercial Officer, received a compensation package of $2.3M, which increased by 1% compared to previous year. 35% of the compensation package, or $805K, was in option awards.
James P. Kelly, Chief Financial Officer, earned $2.2M in 2019, which is about the same as previous year.
Timothy Williams, General Counsel, received $2M in 2019, which decreases by 41% compared to 2018.
Gunther Birznieks, Senior Vice President, Business Development, earned $2M in 2019, which is about the same as previous year.
Related executives
Mihael Polymeropoulos
Vanda Pharmaceuticals
Chief Executive Officer
James Kelly
Vanda Pharmaceuticals
Chief Financial Officer
Gian Reverberi
Vanda Pharmaceuticals
Former Senior Vice President, Chief Commercial Officer
Timothy Williams
Vanda Pharmaceuticals
General Counsel
Gunther Birznieks
Vanda Pharmaceuticals
Senior Vice President, Business Development
You may also like
Source: SEC filing on April 22, 2020.